WallStSmart

Agnico Eagle Mines Limited (AEM)vsNovo Nordisk A/S (NVO)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Novo Nordisk A/S generates 2495% more annual revenue ($309.06B vs $11.91B). AEM leads profitability with a 37.5% profit margin vs 33.1%. NVO appears more attractively valued with a PEG of 4.88. AEM earns a higher WallStSmart Score of 73/100 (B).

AEM

Strong Buy

73

out of 100

Grade: B

Growth: 8.0Profit: 9.0Value: 7.3Quality: 8.5
Piotroski: 6/9Altman Z: 2.83

NVO

Buy

55

out of 100

Grade: C

Growth: 4.0Profit: 10.0Value: 4.7Quality: 4.8
Piotroski: 3/9Altman Z: 2.08
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AEMUndervalued (+47.7%)

Margin of Safety

+47.7%

Fair Value

$415.12

Current Price

$192.07

$223.05 discount

UndervaluedFair: $415.12Overvalued
NVOSignificantly Overvalued (-59.4%)

Margin of Safety

-59.4%

Fair Value

$24.21

Current Price

$36.33

$12.12 premium

UndervaluedFair: $24.21Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AEM6 strengths · Avg: 9.5/10
Profit MarginProfitability
37.5%10/10

Keeps 38 of every $100 in revenue as profit

Operating MarginProfitability
64.7%10/10

Strong operational efficiency at 64.7%

Revenue GrowthGrowth
60.3%10/10

Revenue surging 60.3% year-over-year

Debt/EquityHealth
0.0110/10

Conservative balance sheet, low leverage

Market CapQuality
$89.62B9/10

Large-cap with strong market position

Free Cash FlowQuality
$1.30B8/10

Generating 1.3B in free cash flow

NVO5 strengths · Avg: 9.8/10
P/E RatioValuation
10.4x10/10

Attractively priced relative to earnings

Return on EquityProfitability
60.7%10/10

Every $100 of equity generates 61 in profit

Profit MarginProfitability
33.1%10/10

Keeps 33 of every $100 in revenue as profit

Operating MarginProfitability
44.5%10/10

Strong operational efficiency at 44.5%

Market CapQuality
$165.02B9/10

Large-cap with strong market position

Areas to Watch

AEM2 concerns · Avg: 3.0/10
EPS GrowthGrowth
2.0%4/10

2.0% earnings growth

PEG RatioValuation
28.152/10

Expensive relative to growth rate

NVO4 concerns · Avg: 2.3/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
4.882/10

Expensive relative to growth rate

Revenue GrowthGrowth
-7.6%2/10

Revenue declined 7.6%

EPS GrowthGrowth
-4.7%2/10

Earnings declined 4.7%

Comparative Analysis Report

WallStSmart Research

Bull Case : AEM

The strongest argument for AEM centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 37.5% and operating margin at 64.7%. Revenue growth of 60.3% demonstrates continued momentum.

Bull Case : NVO

The strongest argument for NVO centers on P/E Ratio, Return on Equity, Profit Margin. Profitability is solid with margins at 33.1% and operating margin at 44.5%.

Bear Case : AEM

The primary concerns for AEM are EPS Growth, PEG Ratio.

Bear Case : NVO

The primary concerns for NVO are Piotroski F-Score, PEG Ratio, Revenue Growth.

Key Dynamics to Monitor

AEM profiles as a growth stock while NVO is a declining play — different risk/reward profiles.

AEM carries more volatility with a beta of 0.61 — expect wider price swings.

AEM is growing revenue faster at 60.3% — sustainability is the question.

AEM generates stronger free cash flow (1.3B), providing more financial flexibility.

Bottom Line

AEM scores higher overall (73/100 vs 55/100), backed by strong 37.5% margins and 60.3% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Agnico Eagle Mines Limited

BASIC MATERIALS · GOLD · USA

Agnico Eagle Mines Limited is engaged in the exploration, development and production of mineral properties in Canada, Sweden and Finland. The company is headquartered in Toronto, Canada.

Visit Website →

Novo Nordisk A/S

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novo Nordisk A / S, a healthcare company, is dedicated to the research, development, manufacture and marketing of pharmaceutical products globally. The company is headquartered in Bagsvaerd, Denmark.

Want to dig deeper into these stocks?